-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Lidocaine Hydrochloride API Approved
Category:
发布时间：2024-01-24
【概要描述】
Keeping pace with the arrival of spring, Shijiazhuang Sihua Pharmaceutical Group has maintained steady and rapid progress in R&D and innovation, reaping one success after another. On January 23, the group’s application for lidocaine hydrochloride was approved by the National Medical Products Administration, officially registering it as an active pharmaceutical ingredient for use in marketed dosage forms. This marks the sixth new-product approval the company has secured since the start of the year.
Chasing the arrival of spring, Shijiazhuang Sihua Pharmaceutical Group has been advancing its R&D and innovation with steady momentum and reaping one success after another. On January 23, the group’s application for lidocaine hydrochloride was approved by the National Medical Products Administration, officially registering it as an active pharmaceutical ingredient for use in marketed dosage forms. This marks the sixth new-product approval the company has secured since the start of the year.
According to available information, lidocaine hydrochloride is a local anesthetic and antiarrhythmic agent, primarily used for infiltration anesthesia, epidural anesthesia, surface anesthesia, and nerve block.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has been driven by innovation, closely aligned with national strategic priorities and market demands, and actively advanced an integrated “API-plus-formulation” business strategy. The company has made concerted efforts to build a robust API R&D and innovation platform grounded in industry–university–research collaboration and application, while proactively expanding its upstream and downstream industrial chain footprint. As a result, the pace of strengthening, extending, and completing the value chain has significantly accelerated. The API segment has increasingly demonstrated its exemplary role as a “specialized, refined, distinctive, and innovative” “little giant,” effectively driving continuous optimization of the company’s portfolio of specialty APIs and high-end formulations.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091